All News

In case you missed it, this week we had stories about the availability of the first liquid nonstimulant for ADHD, pharmacy technicians as "vaccine champions," SGLT2i's heart-healthy benefits, and more.

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Check out important updates from the FDA for the week of September 30.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.

See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.

Investigators compared semaglutide and other glucagon-like peptide-1 receptor agonists with dipeptidyl peptidase-4 inhibitors.

In posters presented at the Heart Failure Society of America 2024 Annual Meeting, researchers assessed how substance use disorders impact cardiovascular outcomes.

Among patients with heart failure, researchers aimed to understand the association between social detriments of health and physical frailty.

The once-daily, extended release, oral suspension medication was approved by the FDA in May 2024.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Lea Wolsoncroft of Remedies Pharmacy in Hoover, Alabama, discussed what is going on in her pharmacy practice.

Two posters presented at the Heart Failure Society of America 2024 Annual Meeting looked deeper into the topic of statin use in heart transplant recipients.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Angiotensin neprilysin inhibitors have shown to reduce the risk of death and hospitalization due to heat failure, but high prescription costs are a current barrier.

Vaccination against respiratory viruses such as RSV and the flu are crucial to prevent adverse outcomes in patients with heart failure.

Left ventricular ejection fraction, brain natriuretic peptide, and heart failure-related hospitalizations were among the improved metrics.

Sara T. Thomason discuses the impact of stigma on pharmacists who are dealing with substance use disorder, the importance of mental health care, and how schools support pharmacy students dealing with addiction.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

Catch up on important pain management news from the month of September 2024.

In case you missed it, this week we had stories about pharmacists overcoming substance use disorder, the first new treatment approved for schizophrenia in decades, the Senate-Novo Nordisk hearing on semaglutide prices, and more.

Check out these important FDA updates from the month of September 2024.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”